Lung treatment firm Pulmonx's Q3 revenue up 5%, net loss narrows marginally

Overview

• Pulmonx Q3 2025 revenue rises 5% yr/yr to $21.5 mln

• International revenue grows 15% yr/yr, U.S. revenue up 1%

• Pulmonx reports Q3 net loss of $14 mln, marginally lower than last year

Outlook

• Pulmonx expects 2025 revenue between $89 mln and $90 mln

• Company anticipates 2025 gross margin of approximately 73%

• Pulmonx forecasts 2025 operating expenses of $125 mln to $126 mln

Result Drivers

• INTERNATIONAL REVENUE GROWTH - Driven by global adoption of Zephyr Valve procedures

• ZEHPYR VALVE ADOPTION - Co attributes revenue growth to continued commercial execution and global adoption of Zephyr Valve procedures

• OPERATING EXPENSES - Increase in operating expenses due to clinical, development, and commercial investments

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Pulmonx Corp is $4.50, about 53.6% above its November 11 closing price of $2.09

Press Release: ID:nGNX8k5bW8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)